POLEN

OFFICIAL TITLE: PREOPERATIVE OLAPARIB ENDOMETRIAL CARCINOMA STUDY.

PROJECT DETAILS

A PREOPERATIVE “WINDOW-OPPORTUNITY”, MULTICENTER, PHARMACOKINETIC-PHARMACODYNAMIC STUDY TO EVALUATE THE INHIBITORY EFFECTS OF SINGLE AGENT AZD2281 (OLAPARIB), IN PATIENTS WITH EARLY-STAGE ENDOMETRIAL CARCINOMA.

THE PRIMARY OBJECTIVE OF THIS STUDY IS TO IDENTIFY, IN HUMAN TUMOUR SAMPLES, BIOMARKER CHANGES ASSOCIATED TO SHORT EXPOSURE TO AZD2281 AS POTENTIAL PREDICTORS OF ACTIVITY IN ENDOMETRIAL CARCINOMA (EC). 

THIS IS AN EXPLORATORY STUDY WITH A BIOLOGICAL PRIMARY ENDPOINT. CLINICAL EFFICACY OR SAFETY ARE NOT A PRIMARY OBJECTIVE OF THE STUDY.

POLEN AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

ENDOMETRIAL

0

36

9

Spain

N

SITES

COUNTRY

STATUS

Recruitment  closed

ESMO 2016 – DOWNLOAD THE POSTER

POLEN SITES

SPAIN

Instituto Valenciano de Oncología (IVO)

SPAIN

Hospital Clínic i Provincial de Barcelona

SPAIN

Hospital Clínico San Carlos

SPAIN

Hospital Universitario Reina Sofía

SPAIN

Hospital Universitario Ramón y Cajal

SPAIN

Complejo Hospitalario Universitario de Santiago (CHUS)

SPAIN

Hospital de Granollers

SPAIN

Complejo Hospitalario Universitario A Coruña (CHUAC)

SPAIN

Hospital Álvaro Cunqueiro